查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970899

肉瘤切片檢查市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用戶、地區和競爭格局分類，2021-2031年

Sarcoma Biopsy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肉瘤切片檢查市場預計將從 2025 年的 3.0056 億美元成長到 2031 年的 3.8052 億美元，複合年成長率為 4.01%。

肉瘤切片檢查是一項至關重要的診斷過程，它涉及從軟組織或骨骼中獲取間葉腫瘤的組織樣本，以確定其惡性程度並識別組織學亞型。該市場的主要促進因素是肉瘤發病率的不斷上升，這使得準確、早期診斷以製定有效治療方案的需求變得迫切。此外，微創、影像引導技術（例如穿刺活體組織切片）的日益普及也推動了市場成長，因為與傳統手術切除相比，這些技術具有更高的診斷準確性和更低的患者併發症率。

市場概覽
預測期 2027-2031
市場規模：2025年 3.0056億美元
市場規模：2031年 3.8052億美元
複合年成長率：2026-2031年 4.01%
成長最快的細分市場 可重複使用設備
最大的市場 北美洲

然而，腫瘤異質性為市場帶來了重大障礙。取樣不足可能導致漏診或腫瘤擴散的風險。應對此風險需要先進的病理學專業知識，而資源匱乏的地區往往缺乏此類專業知識。根據美國癌症協會預測，2024年美國預計將新增13,590例軟組織肉瘤病例。如此高的發生率凸顯了精準切片檢查技術的重要性，也強調了醫療保健系統在確保腫瘤準確定性方面所面臨的重任。

市場促進因素

全球骨癌和軟組織肉瘤發生率的上升是全球肉瘤切片檢查市場的主要促進因素，從根本上來說，診斷程序的數量必須相應增加。隨著這些惡性腫瘤負擔的加重，醫療系統被迫擴大切片檢查能力，以確保及時發現和分期。近期流行病學研究結果也印證了這項不斷成長的需求。 2025年4月發表於《BMC公共衛生》的一項題為「軟組織肉瘤的全球負擔」的研究預測，全球病例數將達到約96,200例。為了滿足如此龐大的患者群體的需求，切片檢查處理能力必須相應提高，這將直接增加新興市場和已開發市場對切片檢查設備和耗材的需求，並促使各種篩檢通訊協定的開發。

同時，人工智慧（AI）在診斷影像和病理學領域的應用正在改變市場格局，有效應對腫瘤異質性和診斷準確性方面的關鍵挑戰。人工智慧演算法正被擴大用於輔助病理學家對複雜肉瘤進行亞型分類，從而降低切片檢查不確定率和重複檢測的需求。例如，2025年4月在美國癌症研究協會（AACR）年會上發表的數據顯示，一種基於人工智慧的新型模型能夠以高達95.1%的準確率對兒童肉瘤亞型進行分類。這項技術變革得到了強而有力的資金支持。 2025年7月，美國國家癌症研究所（NCI）報告稱，其肉瘤專科研究卓越計畫（SPORE）本會計年度的資助總額為2,375,406美元。這些投資正在提高診斷的可靠性，並加速高品質、人工智慧賦能的數位病理解決方案的普及應用。

市場挑戰

全球肉瘤切片檢查市場的成長受到腫瘤異質性複雜性的顯著限制。這種複雜性使診斷流程變得複雜。間葉組織腫瘤通常在單一腫塊內表現出多種細胞結構，而標準的組織取樣可能無法捕獲到代表性的惡性細胞。這種變異性明顯增加了診斷結果不準確的風險，導致需要重複檢測，從而加重患者負擔並增加醫療成本。此外，由於擔心不當取樣會導致腫瘤擴散，非專業機構不願進行針刺活體組織切片，使得市場准入僅限於少數高頻活體組織切片中心。

由於缺乏具備準確解讀複雜檢體所需專業知識的病理學家，這項限制進一步加劇。疾病本身的罕見性也直接導致了知識的匱乏，因為全科醫生很少遇到這些獨特的惡性腫瘤。根據美國肉瘤基金會的數據，2024年肉瘤約佔所有成人癌症診斷的1%。由於發病率低，病理學家很少有機會累積足夠的經驗來應對與異質性相關的風險，這造成了瓶頸，限制了先進切片檢查產品在臨床實踐中的應用。

市場趨勢

融合基因檢測技術的出現正在重塑市場格局。這項技術能夠應對間葉腫瘤固有的分子複雜性。由於傳統方法往往無法識別所有與易位相關的亞型，檢查室正擴大將靶向次世代定序） panel納入其常規工作流程。臨床數據支持這一轉變，這些數據表明，與標準方法相比，全面的基因分析具有更高的檢測率。例如，發表於2024年11月《分子診斷雜誌》（Journal of Molecular Diagnostics）的一項研究「SARCP：用於肉瘤基因融合檢測的臨床次世代定序測試」顯示，這種新型NGS測試在分析的652例病例中檢測到了36.5%的基因融合。這顯著提高了組織學觀察不明確的患者的診斷準確性。

同時，為了克服侵入性組織取樣的局限性，液態生物檢體和循環腫瘤DNA分析正逐漸成為一種趨勢。這一趨勢的驅動力在於人們需要非侵入性檢測方法來監測微小殘留病灶，並捕捉單點切片檢查可能遺漏的腫瘤異質性。這些基於血液的檢測效用。發表於2024年5月《臨床腫瘤學雜誌》（Journal of Clinical Oncology）的一項研究「利用客製化循環腫瘤DNA檢測在局部軟組織肉瘤中檢測分子殘留病灶」顯示，局部高危險群軟組織肉瘤患者的基準血液樣本中ctDNA陽性率高達79%，凸顯了該技術在即時監測中的實際應用價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肉瘤切片檢查市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（可重複使用設備、一次性設備）
    • 依最終使用者（醫院、門診手術中心、診斷中心）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肉瘤切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肉瘤切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肉瘤切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肉瘤切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肉瘤切片檢查市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肉瘤切片檢查市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Becton, Dickinson, and Company
  • Argon Medical Devices
  • Cook Group Incorporated
  • UROMED
  • STERYLAB Srl

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24322

The Global Sarcoma Biopsy Market is projected to expand from USD 300.56 Million in 2025 to USD 380.52 Million by 2031, reflecting a CAGR of 4.01%. Sarcoma biopsy serves as a critical diagnostic process involving the collection of tissue from mesenchymal tumors located in soft tissue or bone to ascertain malignancy and identify histological subtypes. The primary catalyst for this market is the increasing prevalence of sarcomas, which creates an urgent need for precise, early-stage diagnosis to enable effective treatment planning. Furthermore, the rising utilization of minimally invasive, image-guided procedures, such as core needle biopsy, facilitates market growth by providing superior diagnostic yields and lower patient morbidity relative to conventional surgical excisions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 300.56 Million
Market Size 2031USD 380.52 Million
CAGR 2026-20314.01%
Fastest Growing SegmentReusable Devices
Largest MarketNorth America

However, the market encounters significant obstacles due to tumor heterogeneity, where inadequate sampling can result in non-diagnostic findings or the risk of tumor seeding. Addressing this risk necessitates highly specialized pathological expertise, which is frequently scarce in resource-limited environments. According to the American Cancer Society, an estimated 13,590 new cases of soft tissue sarcomas were anticipated in the United States in 2024. This substantial incidence rate highlights the critical necessity for accurate biopsy modalities while underscoring the pressure placed on healthcare systems to guarantee precise tumor characterization.

Market Driver

The increasing global incidence of bone and soft tissue sarcomas acts as a primary driver for the Global Sarcoma Biopsy Market, fundamentally necessitating a higher volume of diagnostic procedures. As the burden of these malignancies rises, healthcare systems are forced to expand their biopsy capabilities to ensure timely identification and staging. This growing demand is underscored by recent epidemiological findings; according to a study published in BMC Public Health in April 2025 titled 'Global burden of soft tissue sarcomas,' the number of global cases reached approximately 96,200. This substantial patient population requires a proportional increase in biopsy throughput and has prompted the development of widespread screening protocols, directly boosting the consumption of biopsy devices and supplies in both emerging and developed markets.

concurrently, the integration of artificial intelligence into diagnostic imaging and pathology is transforming the market by addressing key challenges regarding tumor heterogeneity and diagnostic accuracy. AI algorithms are increasingly utilized to support pathologists in subtyping complex sarcomas, thereby lowering the rates of inconclusive biopsies and the necessity for repeat procedures. For example, data presented at the American Association for Cancer Research Annual Meeting in April 2025 revealed a new AI-based model capable of classifying pediatric sarcoma subtypes with precision up to 95.1%. This technological shift is supported by robust financial backing; the National Cancer Institute reported in July 2025 that funding for Sarcoma Specialized Programs of Research Excellence (SPOREs) totaled $2,375,406 for the fiscal year, investments that enhance diagnostic confidence and drive the adoption of premium, AI-compatible digital pathology solutions.

Market Challenge

The growth of the global sarcoma biopsy market is significantly hindered by the complexity of tumor heterogeneity, which complicates the diagnostic workflow. Mesenchymal tumors frequently display diverse cellular structures within a single mass, meaning standard tissue extraction may fail to collect representative malignant cells. This variability poses a distinct risk of obtaining non-diagnostic results, leading to repeat procedures that increase patient burden and healthcare costs. Moreover, the potential for tumor seeding during improper sampling deters the use of needle-based biopsies in non-specialized centers, thereby limiting the accessible market to a select number of high-volume institutions.

This limitation is compounded by a shortage of pathology professionals who possess the niche expertise required to accurately interpret these complex samples. The inherent rarity of the condition contributes directly to this knowledge gap, as general practitioners seldom encounter these distinct malignancies. According to the Sarcoma Foundation of America, sarcomas accounted for approximately 1 percent of all adult cancer diagnoses in 2024. This low incidence rate means few pathologists accumulate sufficient experience to navigate the risks associated with heterogeneity, creating a bottleneck that restricts the widespread utilization of advanced biopsy products in general clinical settings.

Market Trends

The market is being reshaped by the emergence of fusion gene detection assays, which address the molecular complexity inherent in mesenchymal tumors. Because traditional methods often fail to identify all translocation-associated subtypes, laboratories are increasingly incorporating targeted next-generation sequencing panels into their routine workflows. This transition is supported by clinical data demonstrating the superior yield of comprehensive profiling compared to standard techniques. For instance, according to the Journal of Molecular Diagnostics in November 2024, the study 'SARCP, a Clinical Next-Generation Sequencing Assay for the Detection of Gene Fusions in Sarcomas' found that a novel NGS assay detected gene fusions in 36.5% of the 652 analyzed cases, significantly improving diagnostic resolution for patients with ambiguous histological presentations.

In parallel, there is a shift toward liquid biopsy and circulating tumor DNA analysis to overcome the limitations associated with invasive tissue extraction. This trend is driven by the demand for non-invasive modalities capable of monitoring minimal residual disease and capturing tumor heterogeneity that single-site biopsies might miss. The utility of these blood-based assays is becoming increasingly apparent for managing localized disease. As reported in the Journal of Clinical Oncology in May 2024, in the study 'Molecular residual disease detection using bespoke circulating tumor DNA assays in localized soft tissue sarcoma,' baseline blood samples from patients with localized high-risk soft tissue sarcoma showed a ctDNA positivity rate of 79%, highlighting the technology's viability for real-time surveillance.

Key Market Players

  • Becton, Dickinson, and Company
  • Argon Medical Devices
  • Cook Group Incorporated
  • UROMED
  • STERYLAB S.r.l.

Report Scope

In this report, the Global Sarcoma Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sarcoma Biopsy Market, By Product Type

  • Reusable Devices
  • Disposable Devices

Sarcoma Biopsy Market, By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers

Sarcoma Biopsy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sarcoma Biopsy Market.

Available Customizations:

Global Sarcoma Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Sarcoma Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Reusable Devices, Disposable Devices)
    • 5.2.2. By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Sarcoma Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Sarcoma Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Sarcoma Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Sarcoma Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End User

7. Europe Sarcoma Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Sarcoma Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Sarcoma Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Sarcoma Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Sarcoma Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Sarcoma Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Sarcoma Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Sarcoma Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Sarcoma Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Sarcoma Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Sarcoma Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Sarcoma Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Sarcoma Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Sarcoma Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Sarcoma Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Sarcoma Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End User

10. South America Sarcoma Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Sarcoma Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Sarcoma Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Sarcoma Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Sarcoma Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton, Dickinson, and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Argon Medical Devices
  • 15.3. Cook Group Incorporated
  • 15.4. UROMED
  • 15.5. STERYLAB S.r.l.

16. Strategic Recommendations

17. About Us & Disclaimer